Acute and probable chronic Q fever during anti-TNFα and anti B-cell immunotherapy: a case report

BMC Infectious Diseases

Tom Sprong²  Marcel van Deuren⁴  Marrigje Nabuurs-Franssen¹  Alfons A den Broeder³  Teske Schoffelen⁴ 

[1] Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands;Department of Internal Medicine, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands;Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands;Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands

关键词: Serology;    Rituximab;    Adalimumab;    Etanercept;    Anti-TNFα;    Tumor necrosis factor-α;    Rheumatoid arthritis;    Immunosuppression;    Coxiella burnetii;    Q fever;   

Others  :  1127542
DOI  :  10.1186/1471-2334-14-330

 received in 2013-11-19, accepted in 2014-06-09,  发布年份 2014

【 摘 要 】

Background

Q fever is caused by the intracellular bacterium Coxiella burnetii. Initial infection can present as acute Q fever, while a minority of infected individuals develops chronic Q fever endocarditis or vascular infection months to years after initial infection. Serology is an important diagnostic tool for both acute and chronic Q fever. However, since immunosuppressive drugs may hamper the humoral immune response, diagnosis of Q fever might be blurred when these drugs are used.

Case presentation

A 71-year-old Caucasian male was diagnosed with symptomatic acute Q fever (based on positive C. burnetii PCR followed by seroconversion) while using anti-tumor necrosis factor-α (anti-TNFα) drugs for rheumatoid arthritis (RA). He was treated for two weeks with moxifloxacin. After 24 months of follow-up, the diagnosis of probable chronic Q fever was established based on increasing anti-C. burnetii phase I IgG antibody titres in a immunocompromised patient combined with clinical suspicion of endocarditis. At the time of chronic Q fever diagnosis, he had been treated with anti B-cell therapy for 16 months. Antibiotic therapy consisting of 1.5 years doxycycline and hydroxychloroquine was started and successfully completed and no signs of relapse were seen after more than one year of follow-up.

Conclusion

The use of anti-TNFα agents for RA in the acute phase of Q fever did not hamper the C. burnetii-specific serological response as measured by immunofluorescence assay. However, in the presented case, an intact humoral response did not prevent progression to probable chronic C. burnetii infection, most likely because essential cellular immune responses were suppressed during the acute phase of the infection. Despite the start of anti-B-cell therapy with rituximab after the acute Q fever episode, an increase in anti-C. burnetii phase I IgG antibodies was observed, supporting the notion that C. burnetii specific CD20-negative memory B-cells are responsible for this rise in antibody titres.

【 授权许可】

   
2014 Schoffelen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Parker NR, Barralet JH, Bell AM: Q fever. Lancet 2006, 367(9511):679-688.
• [2]Raoult D, Marrie T, Mege J: Natural history and pathophysiology of Q fever. Lancet Infect Dis 2005, 5(4):219-226.
• [3]Botelho-Nevers E, Fournier PE, Richet H, Fenollar F, Lepidi H, Foucault C, Branchereau A, Piquet P, Maurin M, Raoult D: Coxiella burnetii infection of aortic aneurysms or vascular grafts: report of 30 new cases and evaluation of outcome. Eur J Clin Microbiol Infect Dis 2007, 26(9):635-640.
• [4]Schoffelen T, Kampschreur LM, van Roeden SE, Wever PC, den Broeder AA, Nabuurs-Franssen MH, Sprong T, Joosten LA, van Riel PL, Oosterheert JJ, van Deuren M, Creemers MC: Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy. Ann Rheum Dis 2014, 73(7):1436-1438.
• [5]Landais C, Fenollar F, Thuny F, Raoult D: From acute Q fever to endocarditis: serological follow-up strategy. Clin Infect Dis 2007, 44(10):1337-1340.
• [6]van der Hoek W, Versteeg B, Meekelenkamp JC, Renders NH, Leenders AC, Weers-Pothoff I, Hermans MH, Zaaijer HL, Wever PC, Schneeberger PM: Follow-up of 686 patients with acute Q fever and detection of chronic infection. Clin Infect Dis 2011, 52(12):1431-1436.
• [7]Fournier PE, Raoult D: Comparison of PCR and serology assays for early diagnosis of acute Q fever. J Clin Microbiol 2003, 41(11):5094-5098.
• [8]Fenollar F, Fournier PE, Raoult D: Molecular detection of Coxiella burnetii in the sera of patients with Q fever endocarditis or vascular infection. J Clin Microbiol 2004, 42(11):4919-4924.
• [9]Frankel D, Richet H, Renvoisé A, Raoult D: Q fever in France, 1985–2009. Emerg Infect Dis 2011, 17(3):350-356.
• [10]Cobb S, Anderson F, Bauer W: Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953, 249(14):553-556.
• [11]Uddin J, Kraus AS, Kelly HG: Survivorship and death in rheumatoid arthritis. Arthritis Rheum 1970, 13(2):125-130.
• [12]Tilburg JJ, Melchers WJ, Pettersson AM, Rossen JW, Hermans MH, van Hannen EJ, Nabuurs-Franssen MH, de Vries MC, Horrevorts AM, Klaassen CH: Interlaboratory evaluation of different extraction and real-time PCR methods for detection of Coxiella burnetii DNA in serum. J Clin Microbiol 2010, 48(11):3923-3927.
• [13]Wegdam-Blans MC, Kampschreur LM, Delsing CE, Bleeker-Rovers CP, Sprong T, van Kasteren ME, Notermans DW, Renders NH, Bijlmer HA, Lestrade PJ, Koopmans MP, Nabuurs-Franssen MH, Oosterheert JJ: Chronic Q fever: review of the literature and a proposal of new diagnostic criteria. J Infect 2012, 64(3):247-259.
• [14]Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP: The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008, 67(5):713-716.
• [15]Kapetanovic MC, Saxne T, Nilsson JA, Geborek P: Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007, 46(4):608-611.
• [16]Dellacasagrande J, Capo C, Raoult D, Mege JL: IFN-gamma-mediated control of Coxiella burnetii survival in monocytes: the role of cell apoptosis and TNF. J Immunol 1999, 162(4):2259-2265.
• [17]Andoh M, Zhang G, Russell-Lodrigue KE, Shive HR, Weeks BR, Samuel JE: T cells are essential for bacterial clearance, and gamma interferon, tumor necrosis factor alpha, and B cells are crucial for disease development in Coxiella burnetii infection in mice. Infect Immun 2007, 75(7):3245-3255.
• [18]Gómez-Reino JJ, Carmona L, Angel Descalzo M, Group B: Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57(5):756-761.
• [19]Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC, Group B: Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish study group experience. Clin Exp Rheumatol 2008, 26(5):854-859.
• [20]Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ: Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003, 48(7):1853-1857.
• [21]Che H, Lukas C, Morel J, Combe B: Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Joint Bone Spine 2014, 81(3):215-221.
• [22]Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350(25):2572-2581.
• [23]Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48(6):1484-1492.
• [24]Bingham CO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A: Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum 2010, 62(1):64-74.